Abstract
Outcome of patients with adult acute lymphoblastic leukemia(ALL)is poor, and even worse among patients with relapsed/refractory ALL(R/R ALL). New treatments must be taken to overcome drug-resistance to conventional chemotherapy for ALL. Humanized monoclonal antibody and chimeric antigen receptor gene modified T cells have become the focus of treatment in ALL. Lots of clinical trials in multiple research centers are in progress, and the results constantly upgrade which is effectively bring better curative effect and prognosis for R/R ALL patients. This is one of the hot topics at the 56th ASH annual meeting. Key words: Leukemia, lymphocytic, acute; Philadelphia chromosome; Immunotherapy; American Society of Hematology annual meeting
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
